{"id":"NCT01102257","sponsor":"Asbell, Penny, M.D.","briefTitle":"Dry Eye Assessment and Management: Feasibility Study","officialTitle":"Clinical Trial of Essential Fatty Acids for Dry Eye Disease: Feasibility Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-01","primaryCompletion":"2010-07","completion":"2011-03","firstPosted":"2010-04-13","resultsPosted":"2012-08-23","lastUpdate":"2012-08-23"},"enrollment":23,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes","Keratoconjunctivitis Sicca"],"interventions":[{"type":"DRUG","name":"Omega-3 EFA Supplement","otherNames":["Fish oil supplements"]},{"type":"DRUG","name":"Olive Oil","otherNames":[]}],"arms":[{"label":"Omega-3 EFA Supplement","type":"EXPERIMENTAL"},{"label":"Olive Oil","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed \"feasibility\" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statistically relevant data concerning the safety and efficacy of the supplement in patients with dry eye disease.","primaryOutcome":{"measure":"Change on Ocular Surface Disease Index (OSDI)","timeFrame":"90 +/- 14 days following initiation of drug regimen","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":9},"commonTop":["watery eyes","thirst","nausea"]}}